Apple and buy now, pay later (BNPL) payment provider Klarna are joining forces to offer customers the option to lease a new Apple device in the U.S.

The tech giant announced the program, called Apple Upgrade, on Tuesday, and said that customers will be able to lease eligible iPhone, iPad, Mac and Apple Watch devices.

Apple Upgrade offers 12- and 24-month leasing options for iPhone and Apple Watch, and 24- and 36-month leasing options for Mac and iPad. Leasing prices start as low as $17.99 per month for iPhone, $11.99 for Apple Watch, $24.99 for Mac, and $11.99 for iPad.

APPLE RAISES PRICES ON SOME STREAMING SERVICES AS LICENSING COSTS CLIMB

When customers enroll in Apple Upgrade, they can trade in their current device through Apple Trade-In to lower their monthly payments during the leasing term, Apple said. At the end of the leasing term, customers can choose to upgrade to the latest Apple device model, purchase the leased device outright or return it.

APPLE RAISES IPAD AND MACBOOK PRICES AS MEMORY CHIP COSTS SURGE

Ticker	Security	Last	Change	Change %
AAPL	APPLE INC.	336.91	+3.89	+1.17%
KLAR	KLARNA GROUP PLC	18.49	+1.13	+6.51%

Apple announced that it would discontinue its iPhone Upgrade Program and iPhone Payments with the rollout of Apple Upgrade. Both programs allowed qualified customers to purchase an iPhone through a 24-month, interest-free installment loan, while the iPhone Upgrade Program also included AppleCare+ and an option for customers to upgrade their device after 12 payments.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The tech giant’s partnership with Klarna comes as more Americans are choosing BNPL options to finance purchases. About 51% of Americans say they have used installment plans for online purchases, according to a Gallup survey.

While Klarna is best known as a BNPL provider, Apple Upgrade is structured as a lease rather than a traditional BNPL loan.

Apple Upgrade is available through Apple’s website and U.S. Apple Store locations. 

Johnson & Johnson shares climbed to a record high Tuesday, rising 1.99% to $271.20, after the healthcare giant agreed to pay $5.5 billion to settle roughly 76,000 remaining U.S. lawsuits alleging its talc products caused ovarian cancer.

The stock briefly touched an intraday record of $274.90 during Tuesday’s session, extending what has become a sixth consecutive day of gains and pushing the company’s year-to-date rally past 30%.

A Major Legal Overhang Finally Resolved

The proposed settlement addresses litigation that has weighed heavily on Johnson & Johnson’s stock and reputation for more than a decade. The settlement removes what had been the single largest legal and reputational risk hanging over the company for more than a decade, and investors moved quickly to price out that uncertainty following Tuesday’s announcement.

The scope of the agreement is substantial, though it remains contingent on broad participation from plaintiffs’ attorneys. The proposed agreement covers the remaining ovarian talc litigation in federal multidistrict proceedings and related state court cases, though it is contingent on participation from plaintiff firms representing at least 95% of the outstanding claims.

Strong Options Market Activity

The scale of Tuesday’s rally was also reflected in unusually heavy trading activity in the options market, where investors have shown a clear preference for bullish positioning. Options traders have shown a strong preference for calls during this run, with the stock’s 50-day call-to-put volume ratio at the International Securities Exchange, Cboe Options Exchange and NASDAQ OMX PHLX ranking higher than 99% of annual readings, while its 10-day call-to-put ratio has shown similarly elevated bullish positioning.

Building on Strong Second-Quarter Earnings

Tuesday’s settlement-driven rally builds on an already solid foundation established by the company’s most recent earnings report. In its second-quarter 2026 earnings report released July 15, Johnson & Johnson posted adjusted earnings per share of $2.90, topping analyst expectations, on worldwide sales of $25.31 billion, up 6.6% year over year. Following that report, the company raised its full-year sales guidance to a midpoint of $101.1 billion, which would mark the first time in company history that annual revenue exceeds $100 billion.

A Beat-and-Raise Quarter Across Both Segments

The strength of Johnson & Johnson’s second-quarter results extended across both of its major business divisions, giving investors confidence in the company’s underlying growth trajectory even before Tuesday’s legal settlement news. Management raised full-year adjusted earnings-per-share guidance and increased its sales forecast following the July 15 report, signaling continued confidence in both the company’s Innovative Medicine and MedTech segments.

A Regulatory Win in Surgical Robotics Added Momentum

Beyond its earnings results, Johnson & Johnson also secured a significant regulatory milestone in recent weeks tied to its medical technology business, adding another layer of positive sentiment ahead of Tuesday’s settlement news. The company received a high-profile regulatory win involving its new robotic surgical system, known as OTTAVA, a development that gave investors renewed conviction in the company’s MedTech growth story and helped reinforce the stock’s recovery from its 52-week low of $164.23.

A Stock That Has Outperformed the Broader Market

Johnson & Johnson’s rally has significantly outpaced broader market performance in recent weeks, reflecting the combination of strong fundamentals and now the resolution of its long-running legal overhang. JNJ stock has risen 6.19% compared with the previous week, with a 7.79% gain over the past month, and a 56.67% increase over the past year, according to TradingView data. Analysts’ price targets on the stock currently range from a low of $210 to a high of $305, reflecting continued optimism about the company’s growth prospects even after the stock’s substantial run-up.

A Notably Mixed Broader Market Backdrop

What makes Tuesday’s rally particularly notable is that it occurred against a broader market environment that offered little tailwind for most stocks, underscoring how company-specific the catalyst truly was. Against a mixed broader market, with the Dow Jones edging up modestly, the S&P 500 nearly flat, and the Nasdaq facing pressure from a deepening selloff in semiconductor stocks tied to concerns over AI circular-financing arrangements, Johnson & Johnson’s outperformance reflected stock-specific catalysts rather than any broader macro tailwind.

A Long History of Talc-Related Litigation

The ovarian cancer lawsuits at the center of Tuesday’s settlement trace back to claims that Johnson & Johnson’s talc-based products, including its baby powder, were contaminated with asbestos and contributed to cases of ovarian cancer among long-term users. The company has faced tens of thousands of individual lawsuits over the issue in the years since the litigation first began, with previous attempts to resolve the claims through bankruptcy-related legal maneuvers ultimately rejected by courts, keeping the underlying litigation risk hanging over the stock for years.

A Company Built on Two Core Segments

Johnson & Johnson, headquartered with more than 138,000 employees worldwide, operates through two primary business segments that together generate the bulk of its revenue. The company’s Innovative Medicine segment offers products for various therapeutic areas, including oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolic conditions, distributed through retailers, wholesalers, hospitals and healthcare professionals, while its MedTech segment focuses on surgical and medical device technology, including the newly cleared robotic surgical platform.

With the proposed $5.5 billion settlement still contingent on securing participation from plaintiff firms representing at least 95% of outstanding claims, the coming weeks are likely to bring further clarity on whether the agreement can be finalized as structured. Assuming the settlement proceeds as outlined, Johnson & Johnson would remove one of the most significant legal liabilities that has shadowed the company for more than a decade, potentially freeing investors to focus more fully on the company’s underlying growth story across its pharmaceutical and medical technology businesses heading into the second half of 2026.

Shares of glass-maker Corning fell 20% to as much as $114.50 on Tuesday after the company reported slower growth in fiber optics and forecast a lower Q3 sales as against the expectations of market experts, according to Reuters report.

The fall wiped out more than $23 billion in market value of the company.

Although Corning beat second-quarter Wall Street expectations for both earnings and revenue, its forward-looking guidance underwhelmed investors.
The company projected third-quarter core sales of $4.9 billion to $5.0 billion, falling slightly short of analyst forecasts.Investors noted a subtle deceleration in the company’s vital optical communications segment, which grew 32% in Q2 compared to 36% in the prior quarter. This raised fears of a near-term slowdown in capital expenditures from major wireless carriers.

Corning’s stock had more than doubled over the past year due to heavy artificial intelligence infrastructure hype. This rapid surge led analysts to warn of an unsustainable and “onerous” valuation, leading to a pullback.The stock has fallen approximately 12.7% in the last 3 months, risen over 65% in 6 months and surged up to 176% in the last one year, followed by a pull back.
Corning Incorporated is a major American technology company that specializes in specialty glass, ceramics, and optical physics. Corning is famous for creating products like Gorilla Glass for mobile phones, optical fiber, and laboratory equipment.
Before the July 28 crash, the company’s market capitalisation stood at $126.21 billion.

NORTH CHICAGO, Ill. — Shares of AbbVie Inc. advanced 3.2% in morning trading Tuesday, reaching a fresh 52-week high as investors positioned ahead of the company’s second-quarter earnings report and continued to focus on the strength of its immunology portfolio and recent pipeline moves.

AbbVie stock rose $8.20 to $265.05 as of 11:16 a.m. EDT, extending a multi-month rally that has lifted the shares more than 30% over the past three months. The move pushed the stock into new high territory amid elevated interest in the company’s key growth drivers, Skyrizi and Rinvoq, and anticipation of results due Friday, July 31.

The pharmaceutical company is scheduled to report second-quarter 2026 financial results before the market opens on July 31, followed by a conference call. Analysts are watching for updates on revenue growth, the performance of its immunology franchise, and any further commentary on full-year guidance after an earlier adjustment related to acquired in-process research and development expenses.

In the first quarter, AbbVie delivered worldwide net revenues of $15.0 billion, up 12% on a reported basis and 10% on a constant-currency basis. Adjusted earnings per share came in at $2.65, exceeding the consensus estimate of $2.59. The company raised its full-year adjusted EPS guidance at that time.

Chairman and Chief Executive Officer Robert A. Michael said at the time: “AbbVie is off to an excellent start to the year, with first quarter results exceeding our expectations across our diverse portfolio. We are delivering top-tier growth and continue to strengthen our long-term outlook with pipeline advancements and strategic transactions.”

Skyrizi and Rinvoq have remained central to the growth story as AbbVie works through the ongoing erosion of Humira sales following the loss of exclusivity. The two immunology products have driven substantial share gains in their respective markets and have helped the company return to overall growth faster than many initially expected after the Humira patent cliff.

In June, AbbVie announced an agreement to acquire immunology-focused biopharma company Apogee Therapeutics in a deal valued at approximately $10.1 billion net of cash. The transaction, expected to close in the third quarter, was viewed by investors as a meaningful addition to the pipeline and contributed to a sharp one-day gain in the stock at the time of announcement. The company has continued to pursue earlier-stage assets aimed at supporting growth into the next decade.

Earlier in July, AbbVie updated its guidance to reflect acquired IPR&D and milestones expense of $291 million pretax in the second quarter, an unfavorable impact of 17 cents per share on both GAAP and adjusted non-GAAP diluted EPS. As a result, the company guided second-quarter adjusted diluted EPS to a range of $3.57 to $3.61 and full-year 2026 adjusted diluted EPS to $13.91 to $14.11, incorporating the second-quarter charge. The prior full-year range had been higher before the adjustment for the IPR&D expense.

Despite the guidance revision linked to the accounting impact of recent transactions, institutional interest has remained firm and several analysts have maintained or raised price targets. Consensus ratings lean toward Buy, with average targets clustered near current levels and some higher estimates reflecting confidence in the long-term trajectory of Skyrizi, Rinvoq and the broader pipeline.

AbbVie has emphasized its focus on building a diversified portfolio that includes immunology, oncology, neuroscience and other areas. Management has pointed to a clear line of sight to growth through the 2030s supported by on-market products and emerging assets. Recent business development activity has included investments in platforms spanning in vivo CAR-T, next-generation approaches in depression, multiple myeloma and obesity, among others.

The stock’s advance on Tuesday occurred on relatively light volume compared with recent averages, suggesting the move was driven more by positioning and broader sentiment toward defensive growth names in healthcare than by a single discrete catalyst. AbbVie continues to return capital to shareholders through a substantial dividend, currently yielding about 2.6% on an annualized basis following the most recent quarterly declaration of $1.73 per share.

Market participants will scrutinize Friday’s results for sequential trends in Skyrizi and Rinvoq sales, any commentary on competitive dynamics in immunology, progress on the Apogee integration timeline, and whether underlying operational performance supports confidence in the adjusted full-year outlook after the IPR&D adjustment. Oncology and other therapeutic areas will also draw attention as investors assess the balance of the portfolio beyond the two largest growth drivers.

AbbVie, spun off from Abbott Laboratories in 2013, has grown into one of the largest pure-play biopharmaceutical companies by market capitalization, currently valued near $470 billion. Its strategy has centered on replacing the Humira franchise with a broader set of high-growth assets while investing in research and development and selective acquisitions to extend the growth runway.

The shares have benefited this year from a combination of solid operational execution, successful pipeline advancement and a favorable valuation relative to some high-growth peers in the sector. The approach of the second-quarter report has added an incremental catalyst for trading activity as investors look for confirmation that the momentum observed in the first quarter has continued.

Analysts have noted that sustained double-digit growth in the key immunology products would reinforce the investment case even after accounting for the temporary impact of IPR&D charges. Free-cash-flow generation remains a core strength, supporting both reinvestment in the pipeline and ongoing capital returns.

As the market awaits the detailed numbers and management commentary later this week, Tuesday’s gain left AbbVie trading at the upper end of its recent range and near all-time highs on a split-adjusted basis. The performance underscores investor focus on the company’s ability to execute through the post-Humira transition and to convert pipeline opportunities into future commercial successes.

Trading in the broader healthcare sector provided a constructive backdrop, with several large-cap pharmaceutical and biotech names also advancing. For AbbVie specifically, the combination of near-term earnings visibility, the strategic Apogee transaction and continued strength in its core growth brands has kept the stock in favor among investors seeking exposure to large-cap biopharma with a mix of established cash flows and pipeline optionality.

Nearly half of American adults have high blood pressure, and most don’t know it. The condition rarely causes symptoms, but over time it damages blood vessels, strains the heart and raises the risk of stroke and kidney disease. Doctors have long pointed to salt as the main dietary culprit. Increasingly, though, researchers are focused on the other side of the equation: potassium, and the fruits that deliver it.

The science centers on a simple ratio. Sodium and potassium are electrolytes that regulate how the kidneys manage fluid and how blood vessels contract and relax. Too much sodium, or too little potassium, throws that balance off and pushes blood pressure up. New research suggests correcting the ratio by adding potassium-rich fruit may matter as much as cutting salt.

A 2025 study in the American Journal of Physiology-Renal Physiology built computer models simulating how the kidneys, hormones and cardiovascular system respond to different levels of sodium and potassium intake in men and women. The researchers found that boosting potassium significantly lowered blood pressure in both sexes. Anita Layton of the University of Waterloo, one of the study’s authors, said the findings point to a shift in how patients might be counseled. “Our research suggests that adding more potassium-rich foods to your diet such as bananas or broccoli might have a greater positive impact on your blood pressure than just cutting sodium,” Layton said.

Here are seven fruits nutrition experts and recent studies say can help.

Bananas. The fruit most associated with potassium remains a go-to recommendation. A single medium banana provides roughly 400 to 450 milligrams of potassium, along with fiber and a small amount of magnesium. Cardiologist David Sabgir said the mineral works directly against sodium’s effects on the circulatory system. “Bananas are a good source of potassium, which has been shown to help manage hypertension and is recognized for its ability to reduce the effects of sodium in the body and to alleviate tension in the walls of the blood vessels,” Sabgir said. Doctors caution that bananas aren’t a substitute for prescribed medication, and people with kidney disease should talk to a physician before significantly increasing potassium intake, since excess levels can be dangerous.

Avocados. Avocados combine potassium, magnesium, fiber and mostly unsaturated fat — a nutritional profile that fits well into heart-healthy eating patterns. One avocado contains roughly 690 milligrams of potassium and 9 grams of fiber. A 2023 study found women who ate five or more servings of avocado per week had a notably lower rate of hypertension than those who ate less. Registered dietitian Jessica Brantley-Lopez said the fruit’s benefit comes from more than one nutrient working together, since fiber and unsaturated fats have both been linked to cardiovascular health. Swapping avocado for saturated-fat-heavy toppings, like creamy sauces or processed meats, is one way dietitians suggest working it into meals.

Berries. Blueberries, raspberries, blackberries and strawberries all contain anthocyanins, plant pigments researchers believe help blood vessels relax and function more efficiently. Registered dietitian Erin Palinski-Wade said the effect shows up in clinical studies of people already at risk for hypertension. “Studies show that adults at risk for hypertension who regularly eat berries see about a two- to three-point reduction in blood pressure,” she said. Sabgir pointed to the same class of compounds, noting research has tied higher intake of anthocyanins to a reduced risk of heart disease.

Kiwi. Two medium kiwis can supply several hundred milligrams of potassium along with vitamin C, fiber and antioxidant compounds. Some studies have linked regular kiwi consumption to modest improvements in blood pressure and blood vessel function, though researchers caution the evidence base remains limited and it’s premature to describe the fruit as a treatment on its own.

Pomegranate. Pomegranate delivers potassium, fiber and polyphenols that scientists are studying for their effects on blood vessels and oxidative stress. A meta-analysis of 22 randomized trials published in 2024 found a statistically significant drop in blood pressure readings among people who consumed pomegranate products, whether as fruit or juice, though the studies varied in dosage and length. Pomegranate juice alone provides more than 500 milligrams of potassium per cup.

Citrus fruits. Oranges and grapefruit have drawn particular attention from researchers studying dietary patterns rather than single nutrients. A 2021 review of a decade of research found that eating roughly 530 to 600 grams of fruit daily — about the equivalent of four oranges — was associated with better blood pressure management, and citrus fruits specifically were linked to lower blood pressure. Drinking orange or grapefruit juice may offer similar benefits, but grapefruit can interact with common blood pressure medications, so doctors recommend checking with a physician before adding it regularly.

Mango. Mango is a newer addition to the list. One mango provides about 564 milligrams of potassium, 5 grams of fiber and 34 milligrams of magnesium. A small 2022 study found that participants who ate about 1.5 cups of mango daily for eight weeks saw their systolic blood pressure drop by roughly 3.5%. Researchers note the study was small and say larger trials are needed to confirm the effect.

Doctors emphasize that no single fruit works like a medication, and the benefits shown in these studies come from consistent, long-term eating patterns rather than occasional servings. The World Health Organization recommends increasing dietary potassium as one strategy for lowering blood pressure in adults, alongside reducing sodium, maintaining a healthy weight and staying physically active. Whole foods — fruits, vegetables, legumes and nuts — remain the preferred source of potassium over supplements, which can pose risks for people with kidney problems or those on certain heart medications.

For most adults, working more of these fruits into daily meals is a low-risk change with research increasingly on its side. Still, health officials stress that anyone diagnosed with hypertension should treat diet as a complement to medical care, not a replacement for it, and should consult a doctor before making major changes to their potassium intake.